Related Experiment Videos
[Inhibition of lactation with lisuride. CLinical evaluation]
J A Sereno Coló1, M T Navarrete Horta
1Hospital General Dr. Miguel Silva, SSA. Morelia, Mich. México.
Ginecologia Y Obstetricia De Mexico
|January 1, 1994
Summary
Lisuride effectively suppresses lactation and associated discomfort in postpartum women. This study found no rebound lactation, indicating lisuride is a safe option for inhibiting milk production.
Area of Science:
- Reproductive Endocrinology
- Pharmacology
Background:
- Human lactation involves complex neural and endocrine regulation.
- Hormones like prolactin, sex steroids, and corticoids are crucial for lactogenesis.
Purpose of the Study:
- To evaluate the efficacy and safety of lisuride for primary lactation inhibition.
- To assess the impact of lisuride on physiological and symptomatic aspects of lactation.
Main Methods:
- An open-label, prospective study involving 50 women post-delivery (34-41 weeks gestation).
- Participants received lisuride 0.2 mg three times daily for 14 days.
- Lactation suppression was medically indicated; breast changes were systematically evaluated.
Main Results:
- Lactation, present in 87% of patients within 24 hours postpartum, was satisfactorily suppressed.
- Significant reduction in breast pain, engorgement, and discomfort from milk leakage was observed.
- No instances of rebound lactation were reported; 5 patients experienced mild nausea.
Conclusions:
- The dopamine agonist lisuride demonstrates clinical effectiveness for primary lactation arrest.
- Lisuride offers a safe alternative to hormonal compounds, with minimal side effects for lactation inhibition.